124 related articles for article (PubMed ID: 25637063)
21. Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse.
Kelley ME; Dunlop BW; Nemeroff CB; Lori A; Carrillo-Roa T; Binder EB; Kutner MH; Rivera VA; Craighead WE; Mayberg HS
Depress Anxiety; 2018 Oct; 35(10):992-1000. PubMed ID: 30260539
[TBL] [Abstract][Full Text] [Related]
22. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants.
Huang TL; Lee CT; Liu YL
J Psychiatr Res; 2008 Jun; 42(7):521-5. PubMed ID: 17585940
[TBL] [Abstract][Full Text] [Related]
23. A case of retrobulbar optic neuritis caused by duloxetine.
Bicer T; Kosker M; Celikay O; Gurdal C
Cutan Ocul Toxicol; 2016 Sep; 35(3):251-3. PubMed ID: 26362493
[TBL] [Abstract][Full Text] [Related]
24. [With the Characteristics of Chronic Pain Patients, Can the Therapeutic Effect of Antidepressant Duloxetine be Predicted?].
Enomoto T; Sugita M; Katsuta Y; Hori N; Koh K; Saito R; Hasegawa R; Takahashi Y; Sugasawa Y; Yamaguchi K; Isek M; Inada E
Masui; 2016 Oct; 65(10):1005-1008. PubMed ID: 30358274
[TBL] [Abstract][Full Text] [Related]
25. Duloxetine-induced subcortical growth in a patient with major depressive disorder and panic disorder.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(2):E42-3. PubMed ID: 21677225
[No Abstract] [Full Text] [Related]
26. Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression.
Dreimüller N; Schlicht KF; Wagner S; Peetz D; Borysenko L; Hiemke C; Lieb K; Tadić A
Neuropharmacology; 2012 Jan; 62(1):264-9. PubMed ID: 21803060
[TBL] [Abstract][Full Text] [Related]
27. Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial.
Mowla A; Dastgheib SA; Razeghian Jahromi L
Clin Drug Investig; 2016 Jul; 36(7):539-43. PubMed ID: 27071759
[TBL] [Abstract][Full Text] [Related]
28. [Major depressive disorders and BDNF (brain-derived neurotrophic factor)].
Shimizu E; Hashimoto K; Iyo M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Jun; 24(3):147-50. PubMed ID: 15291244
[TBL] [Abstract][Full Text] [Related]
29. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients.
Gonul AS; Akdeniz F; Taneli F; Donat O; Eker C; Vahip S
Eur Arch Psychiatry Clin Neurosci; 2005 Dec; 255(6):381-6. PubMed ID: 15809771
[TBL] [Abstract][Full Text] [Related]
30. Effects of escitalopram on serum BDNF levels in elderly patients with depression: a preliminary report.
Martocchia A; Curto M; Scaccianoce S; Comite F; Xenos D; Nasca C; Falaschi GM; Ferracuti S; Girardi P; Nicoletti F; Falaschi P
Aging Clin Exp Res; 2014 Aug; 26(4):461-4. PubMed ID: 24435333
[TBL] [Abstract][Full Text] [Related]
31. Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients.
Zanardini R; Gazzoli A; Ventriglia M; Perez J; Bignotti S; Rossini PM; Gennarelli M; Bocchio-Chiavetto L
J Affect Disord; 2006 Mar; 91(1):83-6. PubMed ID: 16448701
[TBL] [Abstract][Full Text] [Related]
32. Duloxetine for childhood depression with pain and dissociative symptoms.
Desarkar P; Das A; Sinha VK
Eur Child Adolesc Psychiatry; 2006 Dec; 15(8):496-9. PubMed ID: 16732464
[TBL] [Abstract][Full Text] [Related]
33. Duloxetine-related growth of putamen and brainstem in first-onset drug-naive major depressive disorder with panic disorder: a case series.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(2):E40-1. PubMed ID: 21677224
[No Abstract] [Full Text] [Related]
34. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis.
Polyakova M; Stuke K; Schuemberg K; Mueller K; Schoenknecht P; Schroeter ML
J Affect Disord; 2015 Mar; 174():432-40. PubMed ID: 25553404
[TBL] [Abstract][Full Text] [Related]
35. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
36. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of brain-derived neurotrophic factor are unchanged after transcranial direct current stimulation in treatment-resistant depression.
Palm U; Fintescu Z; Obermeier M; Schiller C; Reisinger E; Keeser D; Pogarell O; Bondy B; Zill P; Padberg F
J Affect Disord; 2013 Sep; 150(2):659-63. PubMed ID: 23664268
[TBL] [Abstract][Full Text] [Related]
38. Duloxetine for the treatment of major depressive disorder.
Nemeroff CB; Schatzberg AF; Goldstein DJ; Detke MJ; Mallinckrodt C; Lu Y; Tran PV
Psychopharmacol Bull; 2002; 36(4):106-32. PubMed ID: 12858150
[TBL] [Abstract][Full Text] [Related]
39. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
40. Atypical Stevens-Johnson syndrome in an adolescent treated with duloxetine.
Strawn JR; Whitsel R; Nandagopal JJ; Delbello MP
J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):91-2. PubMed ID: 21309700
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
